导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.54% | 1811/4773 |
| 近一周 | -2.16% | 3495/5465 |
| 近一月 | 1.34% | 307/5421 |
| 近一季 | 0.63% | 874/5231 |
| 近半年 | -2.53% | 2176/4920 |
| 近一年 | -0.85% | 2902/4394 |
| 近两年 | 39.55% | 1928/2954 |
| 近三年 | 44.85% | 657/2253 |
| 成立以来 | 32.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.51% 717/4961 |
-10.93% 4202/5312 |
- - |
- - |
| 2025 | 16.09% 2487/4813 |
0.78% 1771/3635 |
11.47% 180/4076 |
3.24% 3764/4524 |
0.10% 2223/4813 |
| 2024 | 24.66% 282/3463 |
1.02% 905/2808 |
16.37% 3/3014 |
4.19% 2904/3129 |
1.77% 1032/3463 |
| 2023 | 5.06% 201/2656 |
5.14% 823/2280 |
1.60% 208/2385 |
0.27% 377/2515 |
-1.92% 392/2655 |
| 2022 | -0.30% 39/2207 |
3.27% 44/1919 |
1.61% 1448/2016 |
-14.65% 1127/2113 |
11.32% 147/2208 |
| 2021 | -1.74% 817/1822 |
11.91% 20/1255 |
-2.51% 1209/1330 |
-1.46% 525/1466 |
-8.61% 1586/1822 |
| 2020 | -14.46% 996/1250 |
-16.23% 994/1028 |
3.16% 948/1067 |
-4.54% 1107/1164 |
3.70% 893/1184 |
| 2019 | 14.04% 701/1092 |
12.62% 704/754 |
-4.08% 419/804 |
-8.28% 826/850 |
15.11% 15/918 |
| 2018 | -13.81% 92/834 |
- - |
- - |
- - |
-5.43% 34/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证港股通高股息投资ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |